Since the effects of BCAT1 seem LSC-specific and given that gabapentin is readily available for clinical use, it will be interesting to see whether clinical strategies are being developed to exploit BCAT1 as a therapeutic target in myeloid leukemias. The gene discussed is BCAT1; the disease is myeloid leukemia.